Cardiometabolic Risk

James Matera, DO, on Managing Comorbid CVD, Diabetes, and Kidney Disease

James Matera, DO, from CentraState Medical Center, explains why CVD, diabetes, and kidney disease often occur together, and how the presence of one or more of these conditions can complicate treatment outcomes. He also discusses how the 2017 ACC/AHA hypertension guideline has impacted disease management in this patient population.

For more, visit our Diabetes and Nephrology Resource Centers.

James J. Matera, DO, FACOI, is a nephrologist and Medical Director of Population Health at CentraState Medical Center in Freehold, New Jersey.


1. de Boer IH, Sun W, Cleary PA, et al; DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366-2376. doi:10.1056/NEJMoa1111732.

2. Rosenstock J, Perkovic V, Johanssen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79. doi:10.1001/jama.2018.18269.

3. Das SR, Everett BM, Birtcher KK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: A report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol. 2018. doi:10.1016/j.jacc.2018.09.020.

4. Carey RM, Whelton PK; 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: Synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018;168(5):351-358. doi:10.7326/M17-3203.